Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer

BACKGROUND: We report the re-biopsied diagnosis of a patient with anaplastic lymphoma receptor tyrosine kinase (ALK)-positive lung adenocarcinoma successfully treated with ceritinib 450 mg/day taken with food following disease progression and gastrointestinal intolerance to crizotinib. CASE PRESENTA...

Descripción completa

Detalles Bibliográficos
Autores principales: Won, Brian, Mambetsariev, Isa, Salgia, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969677/
https://www.ncbi.nlm.nih.gov/pubmed/27480287
http://dx.doi.org/10.1186/s12885-016-2636-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969677/
https://www.ncbi.nlm.nih.gov/pubmed/27480287
http://dx.doi.org/10.1186/s12885-016-2636-z

Ejemplares similares